Key result
Cardiomyocyte Hif-1α knockout attenuates HCM in mice, reducing LV wall thickness and fibrosis.
Why the study?
Hif-1a is associated with hypertrophic cardiomyopathy, but its exact role in pathogenesis remains to be elucidated.
Does cardiomyocyte-specific Hif-1a knockout improve the disease phenotype in an α-MHC 719/+ HCM mouse model?
Does cardiomyocyte-specific Hif-1a knockout improve the disease phenotype in an α-MHC 719/+ HCM mouse model?
Cardiomyocyte-specific knockout of Hif-1a attenuates the disease phenotype in a mouse model of hypertrophic cardiomyopathy, suggesting Hif-1α as a potential therapeutic target.
Supports Hif-1α targeting in HCM models; leaves open clinical translation from this animal study.
Hypertrophic cardiomyopathy (HCM) caused by autosomal-dominant mutations in genes coding for structural sarcomeric proteins, is the most common inherited heart disease. HCM is associated with myocardial hypertrophy, fibrosis and ventricular dysfunction. Hypoxia-inducible transcription factor-1α (Hif-1α) is the central master regulators of cellular hypoxia response and associated with HCM. Yet its exact role remains to be elucidated. Therefore, the effect of a cardiomyocyte-specific Hif-1a knockout (cHif1aKO) was studied in an established α-MHC 719/+ HCM mouse model that exhibits the classical features of human HCM. The results show that Hif-1α protein and HIF targets were upregulated in left ventricular tissue of α-MHC 719/+ mice. Cardiomyocyte-specific abolishment of Hif-1a blunted the disease phenotype, as evidenced by decreased left ventricular wall thickness, reduced myocardial fibrosis, disordered SRX/DRX state and ROS production. cHif1aKO induced normalization of pro-hypertrophic and pro-fibrotic left ventricular remodeling signaling evidenced on whole transcriptome and proteomics analysis in α-MHC 719/+ mice. Proteomics of serum samples from patients with early onset HCM revealed significant modulation of HIF. These results demonstrate that HIF signaling is involved in mouse and human HCM pathogenesis. Cardiomyocyte-specific knockout of Hif-1a attenuates disease phenotype in the mouse model. Targeting Hif-1α might serve as a therapeutic option to mitigate HCM disease progression.
No takes yet. Share an insight, caveat, or question.
Murthi et al. (2025) studied Hypertrophic cardiomyopathy (n=31). Cardiomyocyte-specific Hif-1a knockout vs. Wildtype and α-MHC719/+ mice was evaluated on Myocardial hypertrophy and fibrosis. Cardiomyocyte-specific knockout of Hif-1α attenuated the disease phenotype in a mouse model of hypertrophic cardiomyopathy, reducing left ventricular wall thickness and myocardial fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: